Page 34 - 21st Century Perspective - Glaucoma Supplement
P. 34

Every Millimeter Counts



               “The risk reduction could be about 19% per mm Hg, confirming results from the [Early Manifest
               Glaucoma Trial] and Canadian Glaucoma Study, and showing that intraocular pressure reduction is
               highly effective, and that every mm Hg of pressure counts. These results should … serve as a
               stimulus to the pharmaceutical industry to continue development of new and even more potent
               drugs.”


               Source:​ Heijl A. Glaucoma treatment: by the highest level of evidence. ​Lancet​. 2015;385(9975):1264-1266.





               “Elevated IOP is a strong [risk] factor for glaucoma progression, with the [hazard ratio] increasing by
               11% for every 1 mm Hg of higher IOP.”


               Source:​ Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and
               glaucoma progression in the Early Manifest Glaucoma Trial. ​Ophthalmology​. 2007;114(2):205-209.





               “Progression is related to the magnitude of initial IOP change from baseline to the first follow-up visit.
               This initial change in IOP was strongly and inversely associated with progression. Thus, an IOP
               reduction of 1 mm Hg from baseline decreased the risk of progression by about 10% in these
               analyses.”


               Source: ​Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest
               Glaucoma Trial. ​Arch Ophthalmol​. 2003;121(1):48-56.





               “Our current understanding of the relationship between IOP lowering in glaucoma onset and
               progression translates to the effect of each mm Hg IOP reduction on the development of progression
               of visual field loss.”


               Source: ​de Moraes CG, Liebmann JM, Medeiros FA, Weinreb RN. Management of advanced glaucoma: characterization and
               monitoring. ​Surv Ophthalmol​. 2016;61(5):597-615.






                                                                                                          34
   29   30   31   32   33   34   35   36   37   38   39